Goldman Sachs downgraded WuXi Biologics to Neutral from Buy with a price target of HK$21.60, down from HK$50. The firm notes the China CRO/CDMO sector has experienced significant market volatility following the introduction of a draft version of the “BIOSECURE Act” bill in the U.S. House of Representatives on January 25 – and a subsequent, similar bill proposed in the U.S. Senate last week.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on WXIBF: